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Background: PDE12 degrades 2,5-oligoadenylate, a second messenger involved in the antiviral action of interferon.
Results: Inactivation of the PDE12 gene and novel inhibitors of the enzyme render cells resistant to more than one virus.
Conclusion: PDE12 negatively regulates the innate immune response, and inhibitors of PDE12 have antiviral activity.
Significance: PDE12 inhibitors have the potential to be broadly acting antiviral medicines.
2,5-Oligoadenylate synthetase (OAS) enzymes and RNase-L
constitute a major effector arm of interferon (IFN)-mediated
antiviral defense. OAS produces a unique oligonucleotide sec-
ond messenger, 2,5-oligoadenylate (2–5A), that binds and
activates RNase-L. This pathway is down-regulated by virus-
andhost-encoded enzymes that degrade 2–5A. Phosphodiester-
ase 12 (PDE12) was the first cellular 2–5A- degrading enzyme to
be purified and described at a molecular level. Inhibition of
PDE12 may up-regulate the OAS/RNase-L pathway in re-
sponse to viral infection resulting in increased resistance to a
variety of viral pathogens. We generated a PDE12-null cell
line, HeLaPDE12, using transcription activator-like effec-
tor nuclease-mediated gene inactivation. This cell line has
increased 2–5A levels in response to IFN and poly(I-C), a
double-stranded RNAmimic compared with the parental cell
line. Moreover, HeLaPDE12 cells were resistant to viral
pathogens, including encephalomyocarditis virus, human
rhinovirus, and respiratory syncytial virus. Based on these
results, we used DNA-encoded chemical library screening to
identify starting points for inhibitor lead optimization. Com-
pounds derived from this effort raise 2–5A levels and exhibit
antiviral activity comparable with the effects observed with
PDE12 gene inactivation. The crystal structure of PDE12
complexed with an inhibitor was solved providing insights
into the structure-activity relationships of inhibitor potency
and selectivity.
Conventional antiviral drugs target essential viral proteins
such as the RNA or DNA polymerase or protease. Such agents
have provided highly effective medicines for pathogens such as
human immunodeficiency virus and hepatitis C. Drawbacks to
these types of direct acting antiviral agents can be the emer-
gence of resistance or efficacy against a narrow range of strains
within a divergent family. Alternative approaches that augment
host innate defense or target essential host pathways required
by the virus may provide benefit by increasing the barrier to
resistance or by acting against a broad array of viral pathogens.
The discovery of agents with activity against multiple viral
pathogens is particularly appealing to help combat the threat of
emerging diseases like pandemic influenza, severe acute respi-
ratory syndrome,Middle East respiratory syndrome, and Ebola
(1).
The first line of defense against viral infections occurs within
the epithelial cell layer invaded by the pathogen. This function
is regulated in mammalian cells through the biological activity
of type 1 interferon (IFN). The enzymes oligoadenylate synthe-
tase (OAS)2 and RNase-L constitute one of the major effector
pathways of IFN action (2–4). IFN induces the expression of
certainOASenzymes. The activity ofOAS is tightly regulated at
the post-translational level by the binding of pathogen-associ-
ated double-stranded RNA intermediates. Once activated,
OAS polymerizes ATP in a template-independent fashion to a
length of 4–10 nucleotides. Interestingly, OAS produces 2,5-
linked adenylate polymers (2–5A) as opposed to the 3,5-link-
age found in typical nucleic acids like mRNA and DNA.
RNase-L normally exists in an inactive monomeric state. 2–5A
binds to an ankyrin repeat regulatory domain that triggers the
dimerization and activation of the RNase. RNase-L promotes
an antiviral state within the cell through direct cleavage of viral
genomes and intermediates as well as through the regulation of
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acting antiviral agents that augment host innate immune
defense.
Experimental Procedures
Inactivation of the PDE12 Gene—A PDE12-deficient cell line
was generated in a HeLa cell background using TALEN
nuclease-directed genomic breaks (Transposagen Biopharma-
ceuticals, Inc., Lexington, KY). Nonhomologous end-joining of
these breaks generates small deletions leading to frameshift
mutations (20). A cell clone with frameshift mutations in all
alleles of PDE12 was desired, although the exact number of
alleles was unknown. Two TALEN-encoding cDNA constructs
were designed to cleave the first exon of the humanPDE12 gene
downstream of the last alternate ATG start codon at base pair
646 (Homo sapiens chromosome 3, GRCh38 Primary Assem-
bly, NCBI Reference Sequence: NC_000003.12). The target
sites were as follows with the TALEN-binding sites
underlined: (a) TCTTCTTCTTGGACTGAGACTGAT-
GTGGAGGAGCGTGTCTACACCCCGTCCA; (b) TAG-
AGGCTGGGCCTGGCACCTGCACTTTTGACCACCGG-
CATCTCTACACGA. The TALEN constructs were co-
transfected intoHeLa cells (AmericanTypeCultureCollection,
CCL-2). After 1 week of culture, the transfection was repeated,
and the population was sorted to single cells and expanded for
screening. Genomic DNA from candidate clones was isolated
and subjected to quantitative PCR using a probe containing the
targeted region of the TALENs. Clones with no quantitative
PCR signal were further characterized. For these clones, a stan-
dard PCR using primers that span the region targeted by the
TALENs was conducted to amplify the genomic DNA. Several
bacterial clones from each cell clone were obtained and
sequenced to determine the nature of the genomic alteration at
the cut site. One cell clone was identified that showed four
possible frameshift mutations in the PDE12 gene. This clone
was selected for further genomic sequencing andWestern blot
analysis. PDE12 protein levels were determined using anti-
PDE12 (Abcam, catalog no. ab87738, Cambridge, UK) at a
1:1000 dilution loading 40g of total cell protein per lane. This
antibody was generated using a synthetic peptide representing
PDE12 residues 560–609.
Determination of Cellular 2–5A and RNase-L Activation—
Functional 2–5A was measured in cell lysates using purified
RNase-L as a biosensor as described (21). To induce 2–5A pro-
duction, cells were treated with IFN and the double-stranded
RNAmimetic polyinosinic-polycytidylic acid (poly(I-C)). IFN
(Sigma) at 15 units/ml was added to HeLa cells in Minimum
Essential Media, 10% fetal bovine serum, nonessential amino
acids, glutamine, sodium pyruvate, penicillin, and streptomy-
cin. The following day, the cells were detached from the flask
with Cell Dissociation Buffer (Gibco, Life Technologies, Inc.),
counted, and diluted into antibiotic-freemedia to 500,000 cells/
ml. The transfection mixture containing 0.8 g/ml poly(I-C)
(Sigma) and 5l/ml Lipofectamine 2000 in Opti-MEM (Gibco,
Life Technologies, Inc.) media was mixed one to one with the
cells, and 20 l of this mixture was distributed to each well of a
384-well cell culture plate (Greiner Bio-One, Monroe, NC).
The plate was placed in a 37 °C incubator for 3 h. The transfec-
tionmixturewas aspirated, and 25l of ice-cold cell lysis buffer,
specific host mRNAs. High levels of prolonged RNase-L activity 
lead to cell death (5), so it is important that the enzyme be 
tightly regulated. In addition to regulating the synthesis of 
2–5A through OAS, host cells down-regulate the ligand 
through cleavage by 2,5-specific phosphodiesterase (25-
PDE) (6, 7).
Viral pathogens have evolved several mechanisms to over-
come the OAS/RNA-L pathway (4, 8). For example, a conserved 
region in the RNA of poliovirus binds directly to RNase-L and 
inhibits substrate cleavage in a competitive manner (9). 
RNase-L is also inhibited by virus-encoded proteins such as the 
L* protein of Theiler’s virus (10). OAS activation is prevented 
by the influenza A NS1 protein that binds to virus double-
stranded RNA blocking the activation of 2–5A synthesis (11). 
Members of the coronavirus and rotavirus families have been 
shown to encode their own 25-PDEs (12, 13). Thus, inhibition 
of RNase-L activity and inhibition of RNase-L activation 
through regulation of 2–5A appear to be major mechanisms for 
pathogen survival. Consequently, overcoming pathogen inhibi-
tion of this pathway may provide broadly acting antiviral 
therapies.
Although some viruses encode their own 25-PDEs (14), 
others may be dependent upon host cell enzymes to down-
regulate RNase-L. Several host proteins have been shown to 
possess 2–5A-PDE activity, including AKAP7, ENPP1, and 
PDE12. AKAP7 was identified as a potential host 25-PDE due 
to sequence homology with coronavirus NS2 and rotavirus VP3 
proteins that belong to the HH family of nucleotide phosphodi-
esterases (15). Indeed, mouse AKAP7 was able to complement a 
defective mouse hepatitis virus NS2 gene to restore infectivity 
(16). This required deletion of the natural AKAP7 nuclear local-
ization sequence to promote accumulation in the cytoplasm. 
PDE12 was the first 25-PDE to be purified and sequenced (17). 
Small interfering RNA (siRNA) knockdown of PDE12 and an 
inhibitor of PDE12 were found to inhibit the replication of vac-
cinia virus in tissue culture (17). PDE12 belongs to the exonu-
clease-endonuclease-phosphatase (EEP) family of nucleases 
with members that are involved in regulating mRNA through 
cleavage of mRNA polyadenylate tails (18). ENPP1 was found to 
be a potential 25-PDE through evaluation of EEP nuclease 
genes that increased 2–5A degrading activity in cell lysates fol-
lowing transient transfection (19). The role of these host 25-
PDEs in regulating viral infectivity is poorly understood. Anal-
ysis of mRNA expression databases indicates that PDE12 is 
likely to be abundantly expressed in tissues and cell lines. More-
over, PDE12 was purified from bovine spleen as the only major 
25-PDE detected in the tissue homogenate (17). Therefore, 
we chose to evaluate the role of PDE12 in the regulation of 
cellular 2–5A and viral infectivity.
We report that HeLa cells containing TALEN-mediated 
PDE12 gene inactivation have increased IFN induced 2–5A and 
resistance to viral infection. We identified a potent, selective 
compound series that inhibits PDE12 in a 2–5A competitive 
fashion. Treatment of host cells with these inhibitors mimics 
gene inactivation. The first crystal structure of apo-PDE12 and 
a structure of PDE12 bound to an inhibitor are presented. Fur-
ther, refinement of this series may lead to promising broadly
20 mM Tris (pH 7.5), 1% Triton X-100, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM
sodiumvanadate, 8mM sodium fluoridewas added to eachwell.
2–5A in the lysate was detected based upon the ability to acti-
vate purified RNase-L. The lysate was diluted 1 to 120 into
RNase-L assay buffer, 25 mM HEPES (pH 7.5), 10 mM MgCl2,
100 mM NaCl, 0.5 mM CHAPS, 1 mM TCEP, 1 M ATP, 50
g/ml BSA and 5 l was transferred to a 384-well assay plate
(Greiner Bio-one). Purified RNase-L was diluted in assay buffer
to 1.5 nM, and 5l was added to the diluted lysate and incubated
at room temperature for 10 min. The reaction was started by
adding 5 l of RNase-L substrate, 5-fluorescein phosphor-
amidite-UUAUCAAAUUCUAUUUGCCCCAUUUUUUUG-
GUUUA-black hole quencher 1-3 (IntegratedDNATechnol-
ogies, Coralville, IA), diluted in assay buffer to 300 nM. Cleavage
of the substrate was detected as a fluorescence increase at 530
nm (485 excitation) in an Analyst GT plate reader (Molecular
Devices, Sunnyvale CA). The concentration of 2–5A in the
lysate was estimated by comparing the rate of substrate cleav-
age to that produced by a standard curve of purified 2–5A.
RNase-L activation in whole cells was estimated by analyzing
rRNA using an Agilent 2100 Bioanalyzer and RNA 6000 Nano
LabChip kit (Agilent Technologies, Santa Clara CA). HeLa cells
were plated at a density of 400,000 cells per well in a 12-well
plate. The cells were treated with IFN and poly(I-C) for 2 h as
described above in the presence or absence of PDE12 inhibitors.
Total cellular RNA was extracted and analyzed following the
manufacturer’s recommended procedure.
Virus Infection Imaging Assays—Infection of small-airway
epithelial cells (SAEC, Lonza, Basel, Switzerland, catalog no.
SUI CC-2547) by human rhinovirus type A strain 16 (ATCC
catalog no. VR-283HRV16) was measured by quantitative im-
munofluorescence microscopy using an antibody against HRV
capsid protein (QED Bioscience, San Diego, catalog no.18758).
SAEC were diluted into small airway cell growth media (SUI,
Lonza, Basel, Switzerland) to a concentration of 100,000 cells
per ml. HRV16 was added to the diluted cells at the indicated
multiplicity of infection (m.o.i.). For compound testing the
m.o.i. was typically 100. 50l of the infected cells were added to
each well of a 384-well cell culture plate (Greiner Bio-one) and
incubated at 33 °C, 5% CO2 for 5 days. The cells were fixed by
adding 50 l per well of Histochoice (Sigma) followed by
sequential 50-l treatments for 1min eachwith 30, 60, and then
95% ethanol (Sigma). Plates were blocked for 1 h with Dulbec-
co’s phosphate-buffered saline (DPBS) plus 5% goat serum
(Gibco, Life Technologies, Inc.) and then incubated for 1 hwith
anti-HRV antibody diluted 1:1000 in DPBS plus 5% goat serum.
All subsequent steps were conducted in 50 l per well of DPBS
plus 0.3% Triton X-100. The plates were washed three times
(Sigma) and then incubated for 1 h with goat anti-mouse
DyLight 594 labeled secondary antibody diluted 1:500 (Abcam,
CambridgeMA, catalog no. AB96881). The plates were washed
three times and then incubated for 10 min with HCS cell mask
green diluted 1:15,000 (Invitrogen, Life Technologies, Inc.) and
Hoechst 33342 diluted 1:10,000 (Invitrogen, Life Technologies,
Inc.). Three final washes were conducted, and then the plates
were imaged using an IN Cell Analyzer 2000 System (GE
Healthcare). Imageswere collected for three INCell 2000 chan-
nel settings, nuclei (Hoechst), cell boundary (HCS cell mask
green), and HRV capsid protein (DyLight 594) using a 10
objective. Images were segmented using IN Cell Analyzer soft-
ware. Cell boundaries were determined from theHCS cellmask
image. The fraction of cells infected by HRVwas determined as
follows: median per cell of Texas Red signal in no HRV control
wells was used to calculate a background cutoff value. All cells
above themedian background plus threemedian absolute devi-
ations were counted as infected, and all cells below the back-
ground plus three median absolute deviations were counted as
uninfected. Total cell number was determined by counting the
number of nuclei visible in the DAPI channel.
RSV infection of SAEC was determined in a similar fashion
with the following exceptions: RSV strain long (ATCC catalog
no. VR-26) was used for infection at an m.o.i. of 0.01. Incuba-
tion following infection was 4 days. Infected cells were detected
using an antibody to the RSV G glycoprotein at 1:1000 (Milli-
pore, Darmstadt, Germany, catalog no. MAB858-2). HRV and
RSV infection of HeLa and HeLaPDE12 cells were conducted
and analyzed as above only using the indicated cell line, m.o.i.,
and time of incubation described in the figure legends.
EMCVCytopathic Effect Assays (CPE)—For compound stud-
ies, HeLa Ohio cells (European Collection of Cell Cultures, cat-
alog no. 84121901) were cultured in DMEM (Invitrogen, Life
Technologies, Inc., catalog no. 12430), 10% HI FBS 1 Pen-
Strep, 2 mM GlutaMAX (Gibco, Life Technologies, Inc.). The
cells were suspended at a density of 20,000 cells per ml and
mixed with EMCV (Advanced Bioscience Laboratories, Rock-
ville, MD, catalog no. 7022) at m.o.i. of 0.01. 50 l of this mix-
ture was added to each well of a 384-well tissue culture-treated
plate (Costar, Washington, D. C.). Cells without virus were
used as an uninfected control. The plates were placed in a
humidified incubator at 37 °C, 5%CO2 for 3 days, and the num-
ber of cells was determined using CellTiter Glo (Promega,
Madison, WI). Evaluation of the effect of PDE12 gene inactiva-
tion was conducted in similar fashion only using HeLa and
HeLaPDE12 at the indicated amount of virus.
Enzyme Expression and Purification—The following con-
structs were cloned in pET-24 vectors (Addgene, Cambridge,
MA) byPCR-amplified oligonucleotide assembly (22). All of the
sequences were human as follows: (a) PDE12(17–609), PDE12
amino acids 17–609 (NP_808881.3) fused to a FLAG tag (23),
TEV protease cleavage site (24), and a C-terminal His6 tag; (b)
PDE12(155–609), N-terminal His6 tag fused to TEV protease
cleavage site and PDE12 amino acids 155–609; (c) PDE12(155–
609206–233), identical to PDE12 (155–609) with residues
206–233 deleted and Ala, Gly, Ser, inserted as a spacer at resi-
due 206; (d) CNOT6(153–557), N-terminal His6 tag fused to
TEV protease cleavage site and CNOT6 amino acids 153–557
(NP_056270.2); and (e) RNase-L(21–723), RNase-L amino
acids 21–723 (NP_066956) followed by an AviTag (25), TEV
protease cleavage site, FLAG tag, and a C-terminal His6 tag. All
plasmid sequences were verified by DNA sequence analysis.
Protein purification described below was conducted using the
AKTA express system (GE Healthcare). Each protein was puri-
fied to greater than 90% purity as determined by stained SDS-
PAGE analysis. Protein mass was determined by intact protein
mass spectrometry.
gradient from 300 mM to 2 M NaCl. The pooled fractions were
applied to a HiLoad 26/60 Superdex 200 gel filtration column
(GE Healthcare) equilibrated with base buffer. RNase-L was
eluted in two peaks, a higher molecular weight aggregate and a
monomeric species. Monomeric fractions were pooled and
stored at80 °C.
Crystallization and Structure Solution of PDE12—PDE12
proteinswere concentrated to 40mg/ml in 20mMTris (pH8.0),
500mMNaCl, and 5mMDTT. The protein or protein-inhibitor
complex (1:5) was incubated on ice for 2 h. Crystals were grown
by sitting-drop vapor diffusion. 600-nl drops were set with a
Mosquito instrument (TTP LabTech;Melbourne, UK) inMRC
2-well Crystallization plates (Swissci; Zug, SUI) by combining
300 nl of PDE12 protein or protein-inhibitor complex with 300
nl of crystallization buffer. Initial apo-crystals were grown with
the PDE12(155–609) in 0.2 M lithium acetate and 20%
PEG3350. Apo-crystals of PDE12(155–609206–233) were
grown at 4 °C in 0.2 MMgCl2, 0.1 M Tris-HCl (pH 8.5), and 24%
PEG3350. Inhibitor-bound crystals of PDE12(155–609206–
233) were grown at 22 °C in 0.1 M Tris (pH 8.5), 15% PEG20000,
and 25% ethylene glycol. Crystals were harvested and cryo-pro-
tected with 25% glycerol, paraton, or 25% ethylene glycol fol-
lowed by submersion in liquid nitrogen. Data were collected at
beamline CLS-08-ID-1 on a Rayonics MX-300CCD detector
for the initial apo-structure and 21-ID-F on a Rayonics
MX225CCDdetector for the loop-deleted structure. The inhib-
itor-bound structure was collected in-house on a FRE gener-
ator using a Saturn 944 detector. All data were processed
using HKL2000 (26).
The initial apo-PDE12 structure was solved in space group
P212121 by molecular replacement using the program Phaser
(27) as implemented in the Phenix software suite (28). A 279-
residue portion of CNOT6 (Protein Data Bank code 3NGO)
was used as the MR model that spanned residues 29–383 but
included several major deletions, including all of residues
45–52, 111–122, 179–193, 233–246, and 278–301. The miss-
ing regions were built using the program Coot (29) by succes-
sive rounds of refinement in Autobuster (30) interleaved with
DMaveraging in theCCP4 suite (31) andmanual building. Phe-
nix autosolve was also used to assist with the building of the addi-
tional domain and to confirmmanual building. A total of 441 res-
idues were built for each of two copies of the protein in the
asymmetric unit. Final refinementswere completedusing theRef-
mac program (32). Subsequent higher resolution structures were
solved from this initialmodel similarly using Phaser formolecular
replacement and iterative cycles of Buster and Coot.
Encoded Library Technology (ELT) Selections—DNA-tagged
compounds present in our ELT library were selected for bind-
ing to purified PDE12 proteins essentially as described (33, 34).
The indicated proteins were immobilized through the His6 tag
to IMAC tips (PhyNexus, San Jose, CA). Before use, tips were
prewashed in selection buffer, 5 mM MgCl2, 10 mM imidazole,
25 mM HEPES (pH 7.5), 100 mM NaCl, 1 mM TCEP with 1
mg/ml BSA (Ambion, Life Technologies, Inc.), and 0.1 mg/ml
sheared salmon spermDNA (Ambion, Life Technologies, Inc.).
20 g of PDE12(272–609) and 10 g of PDE12(17–609) were
immobilized for 20min at room temperature on the prewashed
IMAC tips, and the tips were washed five times with selection
The plasmid encoding PDE12(17– 609) was transformed 
into Escherichia coli BL21(DE3) cells. Transformed cells were 
grown in 2-liter shake flasks in Luria-Bertani broth (Life Tech-
nologies, Inc.) at 37 °C to A600  0.8 and induced with 0.5 mM 
isopropyl -D-1-thiogalactopyranoside. Incubation was contin-
ued overnight at 20 °C. Cells were pelleted and resuspended in 
30 mM imidazole (pH 8.0), 150 mM NaCl, 10% glycerol, and 
lysed by sonication. The lysate was clarified by centrifuging at 
24,000  g, for 30 min at 4 °C, and the supernatant was loaded 
onto ProBond nickel affinity resin (Invitrogen, Life Technolo-
gies, Inc.). The resin was washed with 55 mM imidazole (pH 
8.0), 150 mM NaCl, 10% glycerol, and the protein was eluted 
with a gradient of 55–500 mM imidazole. Fractions containing 
the expressed protein were determined by SDS-polyacrylamide 
gel staining with Gel-code Blue (Pierce, Life Technologies, 
Inc.). Fractions were pooled, and the NaCl concentration was 
reduced to 50 mM by dilution using 20 mM Tris-HCl (pH 8.0). 
The pooled fractions were loaded onto SP-Sepharose (GE 
Healthcare). The resin was washed with 20 mM Tris-HCl (pH 
8.0), 30 mM NaCl, and the protein was eluted from the resin 
using a 30 mM to 1 M NaCl gradient. The fractions containing 
the PDE12 protein were pooled, and DTT and glycerol were 
added to final concentrations of 5 mM and 5%, respectively.
For crystallization, PDE12(155– 609) protein was expressed 
in BL21(DE3) cells, lysed, and purified on ProBond nickel resin 
as described above. The fractions containing PDE12 protein 
were pooled, and the His6 tag was removed by TEV protease 
digestion overnight at 4 °C. The pooled fractions were dialyzed 
against 20 mM Tris-HCl (pH 8.0), 150 mM NaCl and passed 
across a second nickel affinity column to remove the cleaved 
tag. Unbound protein was pooled, concentrated, and applied to 
a HiLoad 26/60 Superdex 200 gel filtration column (GE Health-
care) equilibrated with 50 mM Tris-HCl (pH 8.0), 100 mM NaCl. 
Fractions containing the expressed protein were pooled, and 
DTT was added to a final concentration of 5 mM before con-
centrating the protein to 40 mg/ml. CNOT6(153–507) was 
expressed and purified as described above.
The plasmid encoding RNase-L was transformed into 
BL21(DE3) cells, and a 1-liter inoculum was added to a 20-liter 
fermenter (Applikon, Delft, The Netherlands) in 2 YT media, 
0.5% glycerol to an initial A600  0.1. Growth was conducted at 
37 °C, 20% dissolved oxygen, with stirring at 300 –900 rpm. 
RNase-L expression was induced with 0.4 mM isopropyl -D-1-
thiogalactopyranoside at A600  3. Glycerol (5 g/liter) was 
added, and the temperature was reduced to 25 °C. Cells were 
harvested by centrifugation at A600  10. Purification was con-
ducted with 50 g of cell paste resuspended in 500 ml of 25 mM 
HEPES (pH 7.4), 300 mM NaCl and lysed by two passages at 
12,000 pounds per square inch through a Rannie pressure 
homogenizer (APV). The lysate was clarified by centrifugation 
at 20,000  g for 45 min. The supernatant was loaded onto a 
5-ml HisTrap column (GE Healthcare) equilibrated with base 
buffer, 25 mM HEPES (pH 7.4), 300 mM NaCl, 10% glycerol, 1 
mM CHAPS, 50 mM imidazole. The bound protein was eluted 
with a 50 –500 mM imidazole gradient. Fractions containing 
RNase-L were pooled and TCEP was added to 1 mM. The 
pooled sample was loaded onto a 5-ml HiTrap heparin column 
(GE Healthcare) equilibrated with base buffer and eluted with a
buffer to remove excess protein. The ELT library (5 nmol) was
diluted in 100 l of selection buffer and passed over the IMAC
tip for 1 h at room temperature. The tip waswashed three times
with selection buffer and two times with DNA and BSA-free
selection buffer. Bound compounds were eluted by passing
DNA- andBSA-free selection buffer heated to 72 °C over the tip
for 10min. The elutedmaterial was passed over a fresh IMAC
tip for 15 min at room temperature to remove any denatured
protein. This procedure was repeated in the second round
and analyzed in the third round. The DNA tags on the bound
compounds were defined by sequencing using a Genome
Analyzer II system (Illumina, San Diego). The sequence data
describing the bound compounds were decoded to deter-
mine the chemical features of compounds that have affinity
to PDE12.
PDE12 and CNOT6 Enzyme Assays—2–5A cleavage assays
were conducted using substrate producedwith purified porcine
OAS1 andATP as described (35). The enzymatic synthesis gen-
erates 5-triphosphate-2,5-linked adenylate oligomers from 2
to 5 nucleotides in length. The different oligomers were sepa-
rated by HPLC and identified by mass spectroscopy. The peak
corresponding to the trimer pppA2p5A2p5A was pooled
and is henceforth referred to as 2–5A substrate. PDE12(17–
609) and CNOT6(153–507) cleave 2–5A into two AMPmono-
mers and one ATP. The AMP product was detected using
AMP-Glo (Promega). Assays were performed in 384-well low
volume black plates (Greiner Bio-One) with compound present
prior to reagent addition. The assay buffer was 25 mM HEPES
(pH 7.5), 5 mM MgCl2, 100 mM NaCl, 0.5 mM CHAPS, 1 mM
TCEP, 130 g/ml nuclease-free BSA. Two l of substrate mix-
ture containing 10 M 2–5A in assay buffer mixed 1 to 1 with
AMP-Glo reagent was added to each well. Two l of enzyme
mixture containing 0.5 nM PDE12 or 2 nM CNOT6 in assay
bufferwas dispensed into eachwell, and the platewas incubated
for 30 min at room temperature. The reaction was terminated
with 2 l of AMP detection reagent, and the plate was incu-
bated at room temperature for 45–60 min. Luminescence was
measured using a Viewlux (PerkinElmer Life Sciences).
Compound Handling, Kinetic Studies, and Data Analysis—
All compounds were dissolved from solid stocks in DMSO.
For IC50 determination, primary data were normalized and
expressed as % inhibition as shown in Equation 1,
%I  100 
U  C1	
C2  C1	
(Eq. 1)
where U is the assay result in the presence of compound; C1 is
the average of the high signal in the absence of compound, and
C2 is the average of the low signal obtained with an appropriate
negative control (no virus for viral assays, or no enzyme for
enzyme assays). For IFN-poly(I-C)-induced 2–5A increase
assays, the data were normalized and expressed % activation
(%A) as shown in Equation 2,
%A  100 
U  C2	
C1  C2	
(Eq. 2)
where U is the assay result in the presence of compound; C1 is
the assay signal from IFN-poly(I-C)-treated cell lysates without
compound; and C2 is the assay background (no added lysate).
IC50 or EC50 values were determined by plotting the compound
concentration (log M) versus %I or %A and fitting the four-
parameter logistic equation to the normalized data as shown in
Equation 3,
y 
B  A  B	
1  10K  x	
n (Eq. 3)
where y %I or %A; Bminimum asymptote; Amaximum
asymptote; x  compound concentration; K  log IC50 or log
EC50; and n represents the slope factor of the inhibition curve
(typically close to 1). The results for each compound are
recorded as pIC50 or pEC50 values (K from the above equa-
tion). All compounds were tested in each assay at least three
times, and the reported results represent the mean
 S.D.
Steady state substrate and inhibitor kinetic experimentswere
conducted in triplicate. The initial rate of AMP production cat-
alyzed by PDE12 or CNOT6was determined from a linear fit of
product formed as a function of time from the 20-min time
course experiments readevery2min.The initial ratewas replotted
versus the substrate concentration (Fig. 6). Vmax and Km values
were determined by fitting Equation 4 to the initial rates,
v 
Vmax S
Km S
(Eq. 4)
where v  initial rate; [S]  concentration of 2–5A or oligoA;
Vmaxmaximum velocity; and Km apparent Michaelis con-
stant. kcat value was calculated from Vmax based on the follow-
ing relationship: Vmax kcat [E], where [E] is the concentra-
tion of enzyme used in the experiment based upon the protein
concentration and purity estimate.
The mode of inhibition analysis for compound 3 was con-
ducted as described above at four fixed concentrations of inhib-
itor. Themode of inhibitionwith respect to 2–5A substrate was
determined by fitting equations describing competitive (Equa-
tion 5), noncompetitive (Equation 6), and uncompetitive
(Equation 7) modes of inhibition to the initial rates (36).
v 
Vmax S
S Km 1 IKi
(Eq. 5)
v 
Vmax S
S Km	 1 IKi
(Eq. 6)
v 
Vmax S
S 1 IKi Km
(Eq. 7)
Nonlinear regressions were conducted using the program
GraphPad Prism (GraphPad Software, San Diego) for enzyme
kinetic studies (Equations 4–7). Normalization and pEC50
determinations were conducted using ActivityBase XE (IDBS,
London, UK).
Effects of PDE12 Gene Inactivation on Viral Infection—The
OAS/RNase-L pathway has been shown to impact viruses with
RNA positive-strand genomes such as EMCV, hepatitis C, and
West Nile (2, 4). Thus, we evaluated the effect of PDE12 gene
inactivation on EMCV and HRV, which have RNA positive-
strand genomes and replicate in HeLa cells. EMCV infection
was determined indirectly by measuring virus-induced CPE.
HeLa CPE after 3 days of infection was dependent on the
amount of virus (Fig. 2B). The fraction of cells remaining as a
function of m.o.i. for each cell line was fit to a four-parameter
logistic curve (see Equation 3). The inflection point (m.o.i.
EC50) for HeLa cell killing was (2.92
 0.02) 104 compared
with (1.91
 0.07) 102 forHeLaPDE12. Thus, HeLaPE12
cells required 65 times more virus to induce the same degree of
CPE after 3 days of infection. We evaluated HRV infection
using a cellular imaging assay that measures the expression of
HRV capsid protein VP2. Interestingly, the fraction of cells
infected by HRV was low on the 1st day of infection but similar
for HeLa and HeLaPDE12 at every level of virus. By day 5, the
fraction of cells infected had progressed significantly in HeLa,
but it had declined slightly in HeLaPDE12 (Fig. 2C). Thus,
PDE12 gene inactivation resulted in significant resistance to
infection by HRV.
The effect of the OAS/RNase-L pathway on infection by
viruses outside the RNA positive-strand group is not as well
studied. RSVhas a negative-strandRNAgenome and efficiently
infects HeLa cells. We evaluated RSV infection using an imag-
ing assay that measures the accumulation of protein G of the
viral envelope. HeLa cells were significantly more sensitive to
infection by RSV than HRV as indicated by the lower m.o.i.
required to establish the infection. By day 2, both HeLa and
HeLaPDE12 were similarly infected in an m.o.i.-dependent
FIGURE 1.Characterizationof frameshiftmutations inHeLaPDE12 cell line.A,WT, structure ofwild-type PDE12mRNA. Exon 1, light blue; Exon 2, dark blue;
Exon 3, purple; coding sequence of EEP nuclease domain, green bar; TALEN nuclease-targeted sequence, red. nt  nucleotide number; M1  N-terminal
methionine; T276 threonine at thebeginningof the catalytic domain. Alleles 1–4, length andpositionsof the first deletednucleotide are shown in red; length
ofopen reading frame is shownbyablackarrow. Last encodedaminoacid residue listedabove.B,WesternblotdetectionofPDE12. Lane1,40gof total cellular
protein from HeLa cells. Lane 2, 40 g of total cellular protein from HeLaPDE12 cells.
Results
Inactivation of PDE12 Gene Alleles in HeLa Cells—HeLa cells 
were chosen for PDE12 gene inactivation because they serve as 
a good host for a variety of viruses. Targeted short genomic 
deletions were created by multiple rounds of transient transfec-
tion of TALEN constructs. Clonal cells were obtained, and one 
cell line was selected that appeared to have four separate PDE12 
alleles each containing a distinct out-of-frame deletion in the 
targeted region of exon 1. To confirm this change, the complete 
PDE12 gene was subjected to PCR amplification followed by 
Ion Torrent AmpliseqTM (Life Technologies, Inc.) sequencing. 
Approximately 2000 complete individually amplified PDE12 
sequences were obtained from the line. Four different out-of-
frame gene deletions were found with no wild-type sequence 
detected (Fig. 1A). These results confirm that the parent HeLa 
cells are tetraploid for the PDE12 locus and that the clone con-
tained a frameshift mutation in the targeted coding region for 
each allele. Western blot analysis was conducted to confirm 
lack of PDE12 expression. Full-length PDE12 protein was read-
ily detected in the parent HeLa line but not in the deletion clone 
(Fig. 1B). This line is subsequently referred to as HeLaPDE12.
Effects of PDE12 Gene Inactivation on Cellular 2–5A Levels—
Purified PDE12 has been shown to cleave 2–5A in vitro (17, 19), 
but it is unknown whether the enzyme controls cellular 2–5A. 
OAS1 activation was induced in two steps in HeLa cells and in 
HeLaPDE12. The cells were treated with IFN overnight to 
induce OAS expression. Following IFN treatment, the cells 
were transfected with the double-stranded RNA mimetic, 
poly(I-C), to activate OAS. The cells were lysed, and 2–5A 
in the lysate was quantified using purified RNase-L as a sensor. 
The HeLaPDE12 cells contained5 times more 2–5A than 
the parental HeLa cells (Fig. 2A).
FIGURE 2. Effect of PDE12gene inactivation on cellular 2–5A levels and viral infection.HeLa (blue) or HeLaPDE12 (red) cells were evaluated as follows. A,
2–5A levels in lysates of cells treated with interferon- and poly(I-C) are shown. B, cytopathic effect after 3 days of EMCV infection as a function of virus
concentration was determined. C, fraction of cells infected by HRV16 was determined by evaluating cells for the presence of HRV capsid protein by immuno-
fluorescence and imaging at the indicatedm.o.i. and time of incubation for infection.D, fraction of cells infected by RSV-L was determined by evaluating cells
for the presence of RSV G protein by immunofluorescence and imaging at the indicated m.o.i. and time of incubation for infection.
The structure of PDE12 shows the protein forms two clear
domains, an N-terminal domain composed of residues 161–
274 and a C-terminal domain composed of residues 275–609
(Fig. 3A). The N-terminal domain of the enzyme is primarily
composed of extended loop regions around a core composed of
a six-strandmeander that forms a two-layer-sandwich. This
domain most closely matches the immunoglobulin portion of
the plant actin-binding protein SCAB1 (37). The C-terminal
domain contains the potential catalytic domain and forms a
mixed multilayer -helix–-strand structure similar to the
other EEP family members. This domain most closely resem-
bles that seen in the CNOT6 enzyme structure (38).
The active site cleft seen in CNOT6 is apparent in the struc-
ture of the PDE12 catalytic domain and contains the positively
charged region expected for enzymes that interact with RNAs
(Fig. 3B). An overlay of the CNOT6 catalytic domain with the
C-terminal domain of PDE12 (Fig. 3C) illustrates the overall
structural similarity between the two enzymes particularly in
the core and active site. The metal-chelating residues in the
active site are conserved betweenPDE12 andCNOT6andover-
lay well within the structure. CNOT6-Glu-240 and PDE12-
Glu-351 form similar direct coordinating interactions to a
Mg2 ion, and CNOT6-Asp-528 and PDE12-Asp-598 are both
hydrogen bonding towater ions that in turn directly coordinate
with a Mg2 ion at the same position in both enzymes.
Although the primary Mg2 ion seen in the active site of
CNOT6 has a corresponding ion readily seen in the electron
density of the active site cleft of PDE12 (Fig. 3D), the second
more loosely bound ion seen in the CNOT6 structure does not
appear to be present in PDE12. PDE12 appears to have a water
molecule near the corresponding location of the second Mg2
PDE12 with compound 3 PDE12 apo
Wavelength 1.54178 0.97872
Resolution range 26.03–1.8 (1.864–1.8) 25.73–1.78 (1.844–1.78)
Space group P 21 21 21 P 1 21 1
Unit cell 56.309 66.532 124.88 90 90 90 56.688 62.554 65.393 90 110.398 90
Total reflections 191,057 155,459
Unique reflections 39,837 (2513) 41,197 (4117)
Multiplicity 4.8 (2.1) 3.8 (3.8)
Completeness (%) 0.92 (66.1) 1.00 (1.00)
Mean I/	(I) 24.45 (2.84) 16.69 (3.61)
Wilson B-factor 18.04 16.21
R-merge 0.054 (0.266) 0.073 (0.402)
R-meas 0.060 (0.332) 0.085 (0.242)
CC1/2 (0.904) (0.863)
Reflections used in refinement 39,836 (2513) 41,193 (4117)
Reflections used for R-free 1254 (67) 1291 (131)
R-work 0.1743 (0.2218) 0.1624 (0.2113)
R-free 0.2114 (0.2410) 0.1975 (0.2428)
No. of non-hydrogen atoms 4113 3851
Macromolecules 3580 3454
Ligands 69 37
Protein residues 449 434
r.m.s. (bonds) 0.014 0.014
r.m.s. (angles) 1.63 1.62
Ramachandran favored (%) 97 98
Ramachandran allowed (%) 2.6 1.8
Ramachandran outliers (%) 0.22 0.23
Rotamer outliers (%) 0.75 1.1
Clash score 1.82 0.87
Average B-factor 21.83 21.15
Macromolecules 20.78 19.93
Ligands 17.57 41.59
Solvent 30.55 30.76
TABLE 1
X-ray structure data collection and refinement statistics
Statistics for the highest resolution shell are shown in parentheses r.m.s. means root mean square deviation.
manner (Fig. 2D). However, with longer incubation, the frac-
tion of cells infected by RSV progressed significantly at a low 
m.o.i. in HeLa cells. In contrast, the fraction of cells infected at 
a low m.o.i. in HeLaPDE12 did not progress. Thus, PDE12 
inactivation did not affect the initial infection but appeared to 
block the spread of RSV.
Crystal Structure of PDE12—The effects of PDE12 gene inac-
tivation suggest that inhibiting PDE12 cleavage of 2–5A may 
enhance the innate immune response to a variety of viruses 
such as the important respiratory pathogens HRV and RSV. 
PDE12 is a member of the EEP nuclease family of enzymes, 
which have not been pursued as drug targets. To provide a 
greater understanding of the enzyme structure and to help 
inform a drug discovery strategy, we pursued the crystal struc-
ture of human PDE12 because no structures of any PDE12 iso-
forms were available. An initial crystal structure was deter-
mined for PDE12 residues 155– 609 at 2.7 Å, which included 
two molecules/asymmetric unit in space group P21 (Protein 
Data Bank code 4Z0V). The structure revealed the majority of 
the enzyme is well ordered with electron density observed for 
nearly all residues with the exception of residues 207–222, 
which appear to be on a disordered loop connecting two adja-
cent anti-parallel -strands. A construct was subsequently cre-
ated that removed these disordered residues that allowed us to 
obtain crystals in space group P212121, which has a smaller unit 
cell that contains only one molecule per asymmetric unit and 
diffracts to beyond 1.8 Å (Table 1). It is unlikely that this dele-
tion influences the binding of substrate or inhibitors due to the 
location of these residues on the face opposite the catalytic 
domain. Moreover, the activity of this construct was similar to 
that of our other PDE12 constructs (data not shown).
ion seen in CNOT6 because there is no clear six-way coordina-
tion expected for a Mg2 ion in PDE12.
There are several other differences between the PDE12 and
CNOT6 structures. In CNOT6, a loop encompassing residues
267–280 extends up and away from the active site forming a
well defined end to the active site cleft. In PDE12, a single tight
-turn at residues 378–379 bridges the -strands forming a
much less defined end to the active site cleft, which may allow
for processing of different or longer substrates. Additionally,
residues 202–204, which help to form one side of the active site
cleft in CNOT6, are replaced by a longer region, residues 308–
315, in PDE12, which form two additional helical turns result-
ing in significant differences for that side of the pocket. These
changes along with several individual amino acid substitutions
(CNOT6-Leu-414:PDE12-Thr-500; CNOT6-Ile-488:PDE12-
Leu-560; CNOT6-Gln-205:PDE12-Val-316; and CNOT6-Asp-
483:PDE12-Gly-555) likely form the basis for differences in
substrate selection and inhibitor binding (Tables 2 and 3).
The two domains within our PDE12 construct have a contact
area involving the loop between residues 168 and 182 on the
N-terminal domain, residues on the interconnecting loop, and
the helical face of the C-terminal domain. The contact has a
surface area of 400 Å2 and is primarily hydrophilic between
the two domains; however, a small hydrophobic core is formed
by residues Phe-172, Met-174, Phe-177, and Pro-274 of the
N-terminal domain with residues Cys-277, Phe-279, Tyr-324,
Tyr-330, and Leu-334 of the C-terminal domain.
Discovery of PDE12 Inhibitors Using ELT—The structure of
PDE12 identified a unique cleft in a catalytic domain shared by
the EEP nuclease family that would provide a potential binding
site for inhibitors.We searched for such inhibitors using ELT, a
novel hit identification platform (39). The technology uses
ultra-large collections of chemotypically diverseDNA-encoded
small molecule libraries. The protein target is immobilized on
beads and incubated with a compound library in solution. Pro-
tein-bound compounds are separated from nonbound com-
pounds and identified by sequencing the DNA tags. The plat-
form features two major benefits, access to a broad set of
chemotypes with vast structural diversity and use of negligible
amounts of target protein. Since its inception, ELT has success-
fully identified tractable hit series for diverse targets (33, 34, 40).
Purified PDE12 was immobilized, and selections were per-
formed to screen a three-cycle library. The DNA-encoded
library (Fig. 4A) utilized two fluorinated aromatic acids in cycle
FIGURE 3. X-ray crystal structure of PDE12. A, ribbon diagram of the overall structure of PDE12 residues 161–609 colored with a gradient from blue to red
beginning at the N terminus. B, surface representation of PDE12 colored by charge density. Blue, positive charge; red, negative charge; white, neutral. C,
comparison between the PDE12 (yellow) and CNOT6 (cyan) overall structure. The Mg2 ion common between the two structures is shown in gray. The Mg2
ion unique to CNOT6 is shown in green. D, electron density around the Mg2 ion in the active site.
TABLE 2
Substrate kinetics and compound 3 inhibition
Substrate and inhibitor steady state kinetic studieswere performedusing the indicated enzyme andnucleic acid substrate. AMP formedwas determined as a function of time
from 20-min progress curves conducted in triplicate, and Equation 4 was fit to the initial rates to determine kcat and Km values, or Equation 5 was fit to determine Ki values
for compound 3. The best fit parameter estimates are shown
 the standard error of the fit.
2–5A OligoA-12
Compound 3, KiKm kcat kcat/Km Km kcat kcat/Km
M s1 M1 s1 M s1 M1 s1 nM
PDE12 103
 4 27
 0.5 2.6 105 280
 100 11
 3 0.39 105 17.5
 0.8
CNOT6 45
 7 6
 0.3 1.3 105 164
 86 2.6
 0.7 0.16 105 10,000
chosen as the starting point for our hit optimization effort
(Fig. 4B).
Structure-Activity Relationships for PDE12 Inhibitors—An
x-ray crystal structure of a complex of PDE12with compound 3
was determined using the 155–609 construct (Fig. 5A, Protein
Data Bank code 4Z2B). Strong electron density for the com-
pound could be seen in the active site, andwewere able to fit the
compound unambiguously by confirming the chirality of the
4.4 n 1.
TABLE 3
Structure-activity relationships for PDE12 inhibitors
Compound dose-response experiments were conducted and analyzed as described under “Experimental Procedures.”PDE12, PDE12 enzyme inhibition; CNOT6, CNOT6 
enzyme inhibition; HeLa 2–5A, IFN and poly(IC)-stimulated 2–5A levels in cell lysate; EMCV, EMCV CPE in HeLa Ohio cells; HRV16, inhibition of HRV16 infection of 
SAEC measured by imaging capsid protein. For inhibition assays, pXC50 represents the negative log of the IC50 in molar (pIC50). For HeLa 2–5A, pXC50 represents negative 
log of the inflection point of the increase (pEC50). The values presented are the mean S.D. from the number of experiments shown in parentheses. For some of the replicate 
experimental determinations, a parameter fit was not obtained because the inflection point was outside the compound concentration range. These values had to be excluded 
from the reported mean: compound 1, PDE12 pIC50 9.1 n  1; HeLa 2–5A pEC50 8.1 n  2. Compound 2, HeLa 2–5A pEC50 4.8 n  2; compound 4, PDE12 pIC50
1, followed by benzimidazole formation with 1456 aldehydes 
(cycle 2), and then the acid functionality was capped with 3157 
amines (cycle 3) to afford an ELT library with 9.19 million enu-
merated compounds. After selections, DNA sequencing was 
conducted, and the sequences were translated to identify the 
structures of the putative PDE12 binders. Several potential 
active compounds were designed and synthesized. Compound 
3 represents one of the first active molecules designed and was
bound species directly (Fig. 5B). Compound 3 shows a very
optimized fit and displays several important ligand-protein
interactions (Fig. 5C). The 6-CN moiety on the indole forms a
favorable hydrogen bonding interaction (2.2 Å) with the back-
bone NH of Thr-500. Any attempts to replace this nitrile with
bioisosteres proved deleterious to potency (data not shown).
The carbonyl at 4-C of the benzimidazole has proximity to the
bottom of the protein pocket making a strong interaction with
the nearby Mg2 ion, which is stabilized by interactions with
several water molecules in the region. Similar to the apo-struc-
ture, we observed only one Mg2 ion in the active site. The
primary alcohol at the 2-position onmorpholine forms a crucial
FIGURE 4. Encoded library structure and initial PDE12 inhibitor. A, schematic of the ELT library used for PDE12 inhibitor structure. The helix represents the
position ofDNA tags used to identify protein-bound compounds followingDNA sequencing.C1 represents the variants in the core structure.C2 represents the
variants found at position R (blue). C3 represents the variants found at position R (green). B, chemical structure of key active compound discovered by ELT
screening, compound design, and synthesis (compound 3). The biological activity for compound 3 is described in Table 3.
FIGURE 5. Co-crystal structure of compound 3 bound to PDE12. A, structure of compound 3 bound to the PDE12 catalytic domain construct, PDE12
(155–609206–233). B, electron density of the inhibitor in the active site. C, schematic representation of the contacts between the inhibitor and PDE12. D,
overlay of inhibited PDE12 (shown in yellowwith a green inhibitor) with CNOT6 enzyme (shown in cyanwith its poly(A) substrate).
compounds in this series did not inhibit CNOT6 even at the
highest concentration tested, 50 M (Table 3).
Effect of PDE12 Inhibitors on Cellular 2–5A, RNase-L Activa-
tion, and Virus Infection—PDE12 gene inactivation resulted in
increased 2–5A induced by IFN and poly(I-C) (Fig. 2A). We
evaluated the effect of PDE12 inhibitors in HeLa cells to deter-
mine whether inhibition of enzyme activity produced the same
effect as gene inactivation. Compound 1 is one of our most
potent PDE12 inhibitors with a pIC50 value for enzyme inhibi-
tion of 9.1. Compound 1 produced a maximum 4-fold increase
in 2–5A levels, which is similar to what was seen with gene
inactivation. The pEC50 value for this effect was 7.7 (Fig. 7A).
This 1.4 log decrease in potency from the pIC50 value for PDE12
enzyme inhibition is consistent for all compounds tested in this
series (Table 3). Compounds in the PDE12 inhibitor series did
not affect CNOT6, the most closely related enzyme to PDE12.
Nevertheless, it remains possible that they could produce bio-
logical effects through unknown proteins. We evaluated the
effect of compound 1 in the HeLaPDE12 cells. The IFN-
FIGURE 6. Kinetic characterization of PDE12 and CNOT6. Substrate and
inhibitor steady state kinetic studies were determined using the indicated
enzyme and nucleic acid substrate. AMP formed was determined as a func-
tion of time from 20-min progress curves, and the initial rates were replotted
as shown. Kinetic parameters determined from these experiments are sum-
marized in Table 1. A, reaction rate as a function of 2–5A concentration. Blue,
PDE12; red, CNOT6. Lines represent fit of the data points to Equation 4. B,
reaction rate as a function of oligoA; blue, PDE12; red, CNOT6. Line represents
fit of the data points to Equation 3. C, inhibition of PDE12 by compound 3 as
a function of 2–5A concentration. Blue, no compound; red, 10 nM compound
3; green, 30 nM compound 3; purple, 90 nM compound 3; orange, 180 nM
compound 3. Lines represent a global fit of the data points to Equation 4 for
2–5A competitive inhibition.
H-bonding interaction (1.4 Å) with Glu-351. Any capping of 
this moiety results in a dramatic drop in potency (data not 
shown). The structure also reveals a-stacking interaction 
between the neighboring phenyl group and Tyr-307. Removal 
of any or both of the phenyl and hydroxyl groups results in a 
drastic drop in potency (compound 4). Alkylation of the indole 
with ethyl (compound 2) improves the potency due to a favor-
able hydrophobic interaction of the ethyl at the edge of the 
receptor. Preparation of the 5-bromobenzimidazole analog 
(compound 1) boosted potency compared with compound 2. 
We hypothesized that substitutions at the 5-benzimidazole 
position impart a steric effect causing the 4-CO to adopt a 
perpendicular orientation with respect to the benzimidazole 
ring maximizing the interaction between the CO and the 
magnesium.
Mode of Action of PDE12 Inhibitors—The PDE12-compound 
3 co-crystal structure indicates that the compound binds in the 
active site cleft that was identified by molecular modeling (41). 
A comparison between the crystal structure of CNOT6 with a 
polyadenylate RNA substrate and our PDE12 compound 3 
complex shows that our inhibitor is occupying nearly the equiv-
alent volume and position in PDE12 as the substrate occupies in 
CNOT6 (Fig. 3D). This implies that the compound may inhibit 
by competing with 2–5A. To evaluate this hypothesis further, 
we conducted steady state substrate kinetic experiments to 
determine the mode of inhibition of compound 3. The initial 
rate of AMP produced was analyzed at five fixed concentrations 
of compound 3 using a range of 2–5A as substrate from 1 to 250 
M (Fig. 6C). The initial rates were analyzed by global curve 
fitting to equations representing competitive (Equation 5), 
noncompetitive (Equation 6), or uncompetitive (Equation 7) 
modes of inhibition. The competitive model provided the best 
fit (R2  0.997) compared with the noncompetitive model 
(R2  0.976) and the uncompetitive model (R2  0.940). The 
competitive Ki value for compound 1 inhibition was 17.5 ( 8) 
nM. Taken together with the crystal structure and modeling 
results, we conclude that compound 3 inhibits PDE12 by com-
peting with 2–5A substrate.
PDE12 is a member of the EEP nuclease family. CNOT6 is the 
most similar enzyme to PDE12 with 31% amino acid sequence 
identity in the EEP nuclease domain (41). PDE12 has been 
shown to be able to cleave typical 3,5-linked oligoA substrates 
(19, 41, 42), but CNOT6 has not been shown to cleave 2–5A 
substrates. We compared the steady state substrate kinetics 
using 2–5A (Fig. 6A) and oligoA (Fig. 6B) for PDE12 and 
CNOT6. kcat and Km values were determined by fitting the ini-
tial rate of AMP formation as a function of substrate concen-
tration to Equation 4. kcat/Km value is generally regarded as the 
key measure of substrate efficiency. PDE12 and CNOT6 cleave 
both substrates efficiently (kcat/Km near 105 M1 s1). PDE12 
prefers 2–5A with a 2-fold higher kcat/Km compared with oli-
goA. CNOT6 also prefers 2–5A. These results suggest that both 
enzymes have a slight preference for cleaving 2,5-oligoadeny-
late. However, chain length differences between 2–5A (3 nucle-
otides) and oligoA (12 nucleotides) may also contribute to the 
observed kinetic parameters. The IC50 values for compounds 
1– 4 were determined for CNOT6 (Table 2). Importantly, the
poly(I-C)-induced level of 2–5A was increased compared with
the parentHeLa line as expected. Compound 1 did not increase
the 2–5A level further at any concentration (Fig. 7A). Thus, the
ability of compounds in this series to increase 2–5A is depen-
dent upon the presence of a functional PDE12 enzyme.
IFN-poly(I-C) induces relatively high levels of cellular 2–5A.
This allows for accurate determination of 2–5A but may differ
from a viral infection.We evaluated the ability of PDE12 inhib-
itors to affect 2–5A in HRV-infected HeLa cells (Fig. 7B). HRV
alone resulted in a 15% increase in 2–5A compared with back-
ground levels observed in uninfected cells. Prior treatmentwith
IFN resulted in a slightly greater increase. Addition of PDE12
inhibitors toHRV-infected cells resulted in a 4–6-fold increase
above the background level. By comparison, 2–5A levels in the
compound-treated, IFN-poly(I-C)-induced cells were typically
20-fold higher than background levels (Fig. 7A).
Activation of RNase-L is the primarymechanism for the anti-
viral effect of 2–5A. High level activation of RNase-L results in
cleavage of rRNA and reduced protein synthesis (2–4). Cellular
rRNAwas analyzed using anAgilent Bioanalyzer (Fig. 7C). IFN-
poly(I-C) treatment of HeLa cells for 2 h resulted in the appear-
ance of a major cleavage product representing 10% of the
detectable 28S rRNA. Addition of compound 1 resulted in a
further increase in the proportion of this cleavage product to
23% indicative of increased RNase-L activation in response to
PDE12 inhibition.
PDE12 inhibitors were evaluated for their antiviral activity
(Table 3). Compound 1 inhibited the EMCV-induced cyto-
pathic effect in HeLa Ohio cells with a pIC50 of 6.7. The com-
pound inhibited HeLa Ohio cell proliferation in the absence of
EMCV infection with a pIC50 of 5.7. Because PDE12 gene inac-
tivation is tolerated in the HeLa cell background, it is possible
the effect on cell proliferation is due to a PDE12-independent
effect. We evaluated the effect of compound 1 on the prolifer-
ation of HeLaPDE12 cells. Compound 1 inhibited the prolif-
eration of bothHeLa andHeLaPDE12 cells with a pIC50 of 5.7.
Thus, the compounds in this series appear to have some anti-
proliferative PDE12-independent activities at higher concen-
trations. Typically, the antiviral activity of these compounds is
10–30-fold more potent than the anti-proliferative activity
(Table 3). Themechanismof the PDE12-independent anti-pro-
liferative activity is unknown.
Our results suggest that PDE12 inhibitors exert an antiviral
effect through modulation of the IFN-induced OAS/RNase-L
effector pathway. This pathway may be altered in the HeLa cell
background due to changes associated with oncogenesis. HRV
replicateswell in human small-airway epithelial cells sowe used
the HRV imaging assay to measure the effect of PDE12 inhibi-
tors in a primary cell host. PDE12 inhibitors blocked the repli-
cation of HRV in these cells (Table 3). For example, compound
1 inhibited HRV infection with a pIC50 of 6.9. In general, the
potency of compounds in this series for 2–5A modulation,
EMCV inhibition, and HRV inhibition correlated with the
potency of PDE12 enzyme inhibition.
Discussion
PDE12 is a widely expressed, abundant 2–5A-degrading
enzyme that may have potential as an antiviral target. Two pre-
vious lines of evidence support the antiviral role for PDE12,
siRNA-mediated knockdown of protein expression and the
effects of an inhibitor of PDE12 enzyme activity (17). The pro-
posed mechanism for this activity is modulation of the IFN-
induced OAS/2–5A/RNase-L pathway, although direct evi-
dence supporting this has not been presented. In addition to
PDE12, virus-encoded 2–5A nucleases and other host enzymes
have been described that possess 2–5A nuclease activity, and
modulation of these genes has been found to influence viral
infectivity (12). Therefore, the role of PDE12 in regulation of
host antiviral defense remains unclear.
We employed TALEN nuclease-mediated gene inactivation
to create a HeLa-derived cell line, HeLaPDE12, with no func-
tional PDE12 expression. HeLaPDE12 cells demonstrated
increased 2–5A compared with the parent HeLa cell line when
treated with IFN and the double-stranded RNA mimic poly-
(I-C). This confirms that PDE12 controls cellular 2–5A levels in
response to stimuli known to activate OAS. PDE12 gene inac-
tivation also resulted in increased resistance to infection by
EMCV, HRV, and RSV. The lack of PDE12 activity did not pre-
FIGURE 7.Cellularmechanismof PDE12 inhibitors. A, 2–5A concentrations
were determined following IFN and poly(I-C) treatment of the indicated cell
line as a function of compound concentration. Blue, HeLa cells; red,
HeLaPDE12 cells. B, 2–5A concentrations were determined in HeLa cells
infected with HRV (m.o.i.  30) after 2 days of infection in the presence or
absence of IFN (100 units/ml) or PDE12 inhibitors (5 M). C, rRNA from HeLa
cells was extracted and analyzed using an Agilent Bioanalyzer. Lane 1,
untreated HeLa cells. Lane 2, HeLa cells treated for 2 h with IFN and poly(I-C).
Lane 3,HeLa cells treated for 2 hwith IFN andpoly(I-C) in the presence of 1M
compound 1. A major cleavage product used to estimate the increase in
RNase-L activation is indicated.
Both ends of the active site appear to bemore open in PDE12
relative toCNOT6. PDE12 contains a double glycine at residues
554–555 compared with Phe-482–Asp-483 in cNOT6 at one
end of the pocket. On the opposite end, CNOT6 contains an
11-residue insertion that provides a well defined end to the
active site cleft. The absence of these residues in PDE12 opens
up the cleft. The significance of these differences is unknown
but may affect cleavage of longer substrates.
At theN terminus, PDE12 contains an immunoglobulin (Ig)-
like domain that interacts with the surface of the catalytic
domain. It is interesting to note that other EEP family enzymes
do not appear to contain this domain. Although the function of
the N-terminal Ig domain remains unknown, we speculate that
itmay function like other Ig domains as an interaction region to
anchor the enzyme to another protein or lipid membrane.
Alternatively, the basic patch on the surface of the Ig domain
(Fig. 3C) could interact with the phosphate backbone of longer
substrates.
PDE12 has been shown to be located in the mitochondrial
matrix and found to have the ability to cleave 3,5-oligoadeny-
late in addition to 2–5A (19, 41, 42). Moreover, overexpression
of PDE12 reduced the levels of key mitochondrial proteins and
rates of oxidative phosphorylation; thus, it appears that PDE12
functions as a mitochondrion-specific deadenylase controlling
gene expression in a fashion similar to other EEP enzymes (41).
In contrast, we have found that PDE12 prefers 2–5A to 3,5-
oligoA as a substrate with a 6.5-fold higher kcat/Km value. In
addition,PDE12 gene inactivation or inhibitionwith smallmol-
ecules results in higher cellular 2–5A in response to OAS acti-
vation. Thus, PDE12 appears to be a biologically relevant regu-
lator of the 2–5A-mediated IFN response as well as a regulator
ofmitochondrial gene expression. The localization of PDE12 to
the mitochondrial matrix confounds our understanding of the
subcellular compartmentalization of the OAS/2–5A/RNase-L
pathway, which is typically thought of as being a cytoplasmic
process. Perhaps a subpopulation of PDE12 is present in the
cytoplasm. In contrast, OAS and RNase-L have been shown to
be associated with mitochondria, so PDE12 may be part of a
larger mitochondrion-associated innate defense response (45–
47). We have found that PDE12 gene inactivation and inhibi-
tors are generallywell tolerated byHeLa cells. The effect of gene
inactivation and inhibitors on mitochondrial biology has not
yet been studied, but these effects will clearly be important in
evaluating the potential of PDE12 inhibition for antiviral
therapy.
As discussed in the Introduction, other host enzymes in the
LigT-like group of 2H phosphodiesterases, including AKAP7
have been shown to degrade 2–5A (14). Moreover, EEP
nucleases, including EPP1 (19) and CNOT6, have been shown
to possess this activity. Thus, it seems that mammalian cells
have evolved multiple mechanisms for down-regulating the
OAS/2–5A/RNase-L pathway. The alternative subcellular
localization of these enzymes or other levels of regulation may
be important for preventing excessive RNA degradation and
subsequent cellular damage. From a practical perspective, the
redundancy within the host cell as well as virus-encoded 2–5A-
cleaving enzymes may complicate the utility of future agents
targeting these enzymes.
vent the expression of HRV or RSV structural proteins in the 
early stages of HeLaPDE12 infection, but the spread of infec-
tion observed at lower levels of virus was significantly reduced 
compared with infection of the parental HeLa cells (Fig. 2, C 
and D). The delayed antiviral response may be attributed to the 
time required for the host cells to respond to the initial infec-
tion, induce IFN, induce OAS, and then accumulate 2–5A to 
activate the antiviral protein RNase-L.
Host targets like PDE12 may provide a means for break-
through discoveries of therapeutic agents with broadly acting 
antiviral potential. Phosphodiesterases like PDE4 and PDE5 
have proven to be tractable drug targets for a variety of indica-
tions, including inflammation and erectile dysfunction, respec-
tively (43). Despite its name based upon an ability to break the 
phosphodiester bonds linking the adenylate monomers of 
2–5A, PDE12 is not a member of the cyclic nucleotide phos-
phodiesterase superfamily that contains the enzymes PDE1 
through PDE11. PDE12 is a member of the EEP superfamily of 
deadenylases based upon amino acid sequence homology of 
active sites. Other EEP enzymes that include CNOT6, Noc-
turnin, and ANGEL control a range of biological activities by 
regulating typical 3,5-poly(A) tail length and subsequent RNA 
stability (18). Small molecule inhibitors of enzymes in the EEP 
nuclease family have not been reported. Therefore, we elected 
to initiate our drug discovery effort using ELT, an approach that 
selects enzyme-binding small molecules from extremely 
diverse chemical libraries (39). Based upon an analysis of ELT 
compounds that bound PDE12, we generated a series of small 
molecule inhibitors with representatives described in Table 3. 
Treatment of host cells with these compounds modulates cel-
lular 2–5A, activates RNase-L, and imparts resistance to viral 
infection in a fashion that mimics PDE12 gene inactivation. 
These molecules may represent attractive starting points for 
host-directed antiviral drug discovery.
To further our understanding of the enzyme and aid com-
pound design, we determined the x-ray crystal structures of 
PDE12 in the apo-state and with the enzyme bound to com-
pound 3. The structures of PDE12 reveal similarities with other 
members of the nuclease family. Nearly all of the residues deter-
mined to play a role in the catalytic mechanism for APE1 (44) 
are conserved in similar hydrogen bond networks and struc-
tural alignment in PDE12. These residues include Asp-561, 
His-599, a water molecule, the Mg2 ion, Glu-351, Asn-301, 
Asn-498, and Asp-496 leading us to believe that the catalytic 
mechanism is the same as what was elucidated for other mem-
bers of this family. Comparison of PDE12 and CNOT6 reveals 
important differences that may account for substrate prefer-
ence and inhibitor binding specificity within the EEP subfamily 
of nucleases. PDE12 has an insertion of four residues to extend 
two short helices on one side of the substrate pocket and a 
number of single residue differences at positions 316, 500, 555, 
and 560. These changes result in overall differences in the 
shapes of the PDE12 and CNOT6 substrate pockets presenting 
unique surfaces involved in substrate and inhibitor binding. 
However, the pockets of both enzymes are large and open rel-
ative to the conserved geometry of the catalytic residues that 
may explain the observed flexibility in substrate selection 
(Table 2).
Despite the uncertainty around the role of PDE12 in mito-
chondrial biology or the role of other 2–5A-cleaving enzymes
in the regulation of the IFN-mediated antiviral response, it is
clear that blocking PDE12 activity through gene inactivation or
with small molecules enhances cellular resistance to viral
pathogens, including EMCV, HRV, and RSV. Whether or not
this effectwill extend to other viruses is not known, but a variety
of important pathogens are affected bymodulation of OAS and
RNase-L, including West Nile virus, Chikungunya virus, Den-
gue virus, and hepatitis C virus (5, 48–52). To test whether the
PDE12 inhibitor-induced cellular resistance will translate to a
beneficial effect in vivo will require the production of PDE12
knock-out animals or the development of compounds with suf-
ficient potency and exposure for in vivo antiviral studies.
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